依达拉奉右莰醇对阿替普酶溶栓后MMP-9、ICAM-1、ET-1的影响及临床疗效分析  

Effect of Edaravond-dexcamphenol on MMP-9 ICAM-1 and ET-1 after thrombolytic therapy with alteplase and analysis of clinical efficacy

作　　者：杜文 袁波 李燕平 谭莉 李九玖 夏志伟 Du Wen;Yuan Bo;Li Yanping;Tan Li;Li Jiujiu;Xia Zhiwei(Department of Neurology,Hunan Brain Hospital,Affiliated Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)

机构地区：[1]湖南中医药大学临床医学院,湖南省脑科医院(湖南省第二人民医院)神经内科,长沙410007

出　　处：《脑与神经疾病杂志》2023年第11期693-698,共6页Journal of Brain and Nervous Diseases

基　　金：中国卒中学会-启航基金(2021-2-21)。

摘　　要：目的探讨依达拉奉右莰醇对阿替普酶溶栓后血清细胞间黏附分子(ICAM-1)、内皮素-1(ET-1)、血浆基质金属蛋白酶(MMP-9)水平.方法选取湖南省脑科医院2021年12月-2022年12月急性期缺血性脑卒中(AIS)患者80例,随机分为对照组和观察组.对照组:阿替普酶溶栓治疗后标准化治疗;观察组:阿替普酶溶栓治疗后标准化治疗+依达拉奉右莰醇注射液,疗程2w.评估临床疗效、临床症状评分、美国国立卫生研究所卒中量表(NIHSS)评分、ALBERTA卒中项目早期CT量表(ASPECTS)评分、Barthel(BI)指数评分,检测血液中MMP-9、ET-1、ICAM-1水平变化.结果观察组有效率高于对照组(P<0.05).治疗后,2组患者NIHSS评分、临床症状评分均降低(P<0.01),ASPECTS、BI指数评分均升高(P<0.01),血清MMP-9、ET-1、ICAM-1含量水平均降低(P<0.01),以观察组变化更明显(P<0.01).结论依达拉奉右莰醇注射液能明显抑制阿替普酶溶栓后患者的MMP-9、ET-1、ICAM-1细胞因子的表达,改善AIS超早期阿替普酶静脉溶栓患者临床症状,疗效确切.I Objective To investigate the effects of Edaravond-dexcamphenol on serum intercellular adhesion molecule(ICAM-1),endothelin-1(ET-1)and plasma matrix metalloproteinase(MMP-9)levels after alteplase thrombolytic therapy and its clinical efficacy.Methods A total of 80 patients with acute ischemic stroke(AIS)from December 2021 to December 2022 were selected from Hunan Brain Hospital and divided into control group and observation group.Control group:standardized treatment after alteplase thrombolytic therapy;Observation group:Standardized treatment after alteplase thrombolytic therapy+Edaravone dexcamphol injection,a course of 2 weeks.Clinical efficacy,clinical symptom score,National Institute of Health Stroke Scale(NIHSS)score,ALBERTA Stroke Project Early CT Scale(ASPECTS)score,Barthel(BI)index score,the serum levels of MMP-9,ET-land ICAM-1were determined.Results The effective rate of observation group was higher than control group(P<0.05).After treatment,NIHSS score and clinical symptom score were decreased in 2 groups(P<0.01),ASPECTS and BI index scores were increased(P<0.01),serum contents of MMP-9,ET-1 and ICAM-1 were decreased(P<0.01),and the changes were more significant in observation group(P<0.01).Conclusions Edaravond-dexcamphorol injection can significantly inhibit the expression of MMP-9,ET-1 and ICAM-1 cytokines in patients after alteplase thrombolytic therapy,and improve the clinical symptoms of ultra-early alteplase intravenous thrombolytic therapy in patients with AIS.

关 键 词：依达拉奉右莰醇注射液 阿替普酶 血浆基质金属蛋白酶-9 内皮素-1 血清细胞间黏附分子-1 临床疗效 

分 类 号：R743.32[医药卫生—神经病学与精神病学]